SCHEMBL237148

SCHEMBL237148

C#CC1(O)CCCCCC1

nearest known ligand 0.52

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.52
MEN1 O00255 1/20 0.34
POLB P06746 1/20 0.34
KMT2A Q03164 1/20 0.34
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL36060 1.00
SCHEMBL27743621 1.00 ALDH1A1 (0.52) ALDH1A1MEN1POLBKMT2ANPSR1
SCHEMBL234923 1.00 ALDH1A1 (0.52) ALDH1A1MEN1POLBKMT2ANPSR1
SCHEMBL4418020 1.00 ALDH1A1 (0.52) ALDH1A1MEN1POLBKMT2ANPSR1
SCHEMBL12948617 1.00 ALDH1A1 (0.52) ALDH1A1MEN1POLBKMT2ANPSR1
SCHEMBL31315866 1.00 ALDH1A1 (0.52) ALDH1A1MEN1POLBKMT2ANPSR1
SCHEMBL9841137 1.00 ALDH1A1 (0.52) ALDH1A1MEN1POLBKMT2ANPSR1
SCHEMBL4414709 1.00 ALDH1A1 (0.52) ALDH1A1MEN1POLBKMT2ANPSR1
SCHEMBL4455914 0.97 ALDH1A1 (0.50) ALDH1A1MEN1POLBKMT2ANPSR1
SCHEMBL8204435 0.97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3245256-A1 ORGANOPOLYSILOXANE PREPOLYMER AND CURABLE ORGANOPOLYSILOXANE COMPOSITION COMPRISING SAME Henkel AG & Co. KGaA (DE) 2017-11-22 EP claimed
WO-2016112487-A1 ORGANOPOLYSILOXANE PREPOLYMER AND CURABLE ORGANOPOLYSILOXANE COMPOSITION COMPRISING SAME HENKEL (CHINA) COMPANY LIMITED (CN) 2016-07-21 WO claimed
EP-2516569-B1 HYDROSILYLATION REACTION INHIBITORS, AND USE THEREOF IN A COATING METHOD BLUESTAR SILICONES FRANCE (FR) 2016-07-20 EP claimed
US-20120328787-A1 HYDROSILYLATION REACTION INHIBITORS, AND USE THEREOF IN A COATING METHOD BLUESTAR SILICONES FRANCE (FR) 2012-12-27 US claimed
EP-2516569-A1 HYDROSILYLATION REACTION INHIBITORS, AND USE THEREOF IN A COATING METHOD Bluestar Silicones France (FR) 2012-10-31 EP claimed
WO-2011076710-A1 HYDROSILYLATION REACTION INHIBITORS, AND USE THEREOF IN A COATING METHOD BLUESTAR SILICONES FRANCE (FR) 2011-06-30 WO claimed
EP-4714225-A1 COMPOSITION FOR HIGH-RESILIENT THERMALLY CONDUCTIVE GAP PAD Henkel AG & Co. KGaA (DE) 2026-03-25 EP disclosed
EP-4240433-B1 MEDICAL SILICONE PRESSURE-SENSITIVE ADHESIVE COMPOSITION ELKEM SILICONES SHANGHAI CO LTD (CN) 2025-12-24 EP disclosed
US-20250352692-A1 MEDICAL SILICONE PRESSURE-SENSITIVE ADHESIVE COMPOSITION ELKEM SILICONES FRANCE SAS (FR) 2025-11-20 US disclosed
US-12453800-B2 Medical silicone pressure-sensitive adhesive composition ELKEM SILICONES SHANGHAI CO., LTD. (CN) 2025-10-28 US disclosed
US-20250304576-A1 IKK INHIBITORS CANCER RESEARCH TECH LTD (GB) 2025-10-02 US disclosed
WO-2025118170-A1 THERMALLY CONDUCTIVE SILICONE ADHESIVE COMPOSITION HENKEL AG & CO. KGAA (DE) 2025-06-12 WO disclosed
EP-4522597-A1 IKK INHIBITORS Cancer Research Technology Limited (GB) 2025-03-19 EP disclosed
US-5827883-A TOPICAL DRUG DELIVERY; SIDE EFFECT REDUCTION HOFFMANN-LA ROCHE INC. (US) 1998-10-27 US disclosed
CN-1168103-A Dermatological use of vitamin D derivs. HOFFMANN LA ROCHE (CH) 1997-12-17 CN disclosed
EP-0805682-A1 DERMATOLOGICAL USE OF VITAMIN D DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 1997-11-12 EP disclosed
WO-1996022776-A1 DERMATOLOGICAL USE OF VITAMIN D DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 1996-08-01 WO disclosed
US-4111917-A POLYURETHANES W. R. GRACE & CO. (US) 1978-09-05 US disclosed
US-3979311-A MIXTURE OF AN ALKYNYL CYCLOALKANOL AND AN N,N'-DICYCLOALKYL-THIOUREA UNIVERSAL OIL PRODUCTS COMPANY (US) 1976-09-07 US disclosed
US-3969260-A ALKYNYL CYCLOALKANOL, N,N'-DICYCLOALKYL THIOUREA, POLYAMINOMETHYLENEPHOSPHONATE UNIVERSAL OIL PRODUCTS COMPANY (US) 1976-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304576-A1 IKK INHIBITORS NFKBIA, IKBKE, IKBKB ALDH1A1 4083/4885MEN1 2339/4885POLB 903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.